Literature DB >> 20703083

Cooperativity of Cdk4R24C and Ras in melanoma development.

Rachna Chawla1, Judith A Procknow, Ramana V Tantravahi, Jasvir S Khurana, Judith Litvin, E Premkumar Reddy.   

Abstract

The importance of the CDK4 protein in human cancer first became evident following the identification of a germ line mutation in the Cdk4 locus that predisposes humans to melanoma. This mutation results in substitution of arginine with cysteine at position 24 (R24C). In an earlier study, we introduced the R24C mutation into the Cdk4 locus of mice using Cre-loxP-mediated "knock-in" technology and observed a very low incidence of spontaneous melanomas in Cdk4(R24C/R24C) mice. This suggested that additional oncogenic mutations might be required for development of melanomas. Here we report an increased incidence of spontaneous cutaneous melanoma in mice expressing the oncogene HRAS(G12V) in melanocytes on a Cdk4(R24C) background. Treatment of Tyr-HRas:Cdk4(R24C/R24C) mice with the carcinogen, DMBA/TPA resulted in a further increase in the number of nevi and melanomas developed when compared with Tyr-HRas:Cdk4(+/+) mice. In summary, in Tyr-HRas:Cdk4(R24C/R24C) mice, we observed that activated CDK4 cooperates with the oncogenic HRAS(G12V) protein to increase the susceptibility of melanoma development in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20703083      PMCID: PMC3041165          DOI: 10.4161/cc.9.16.12632

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  21 in total

1.  Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence.

Authors:  Sushil G Rane; Stephen C Cosenza; Richard V Mettus; E Premkumar Reddy
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

2.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

Authors:  A Demunter; M Stas; H Degreef; C De Wolf-Peeters; J J van den Oord
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

3.  Essential role for oncogenic Ras in tumour maintenance.

Authors:  L Chin; A Tam; J Pomerantz; M Wong; J Holash; N Bardeesy; Q Shen; R O'Hagan; J Pantginis; H Zhou; J W Horner; C Cordon-Cardo; G D Yancopoulos; R A DePinho
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

4.  Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes.

Authors:  J Cangiarella; W F Symmans; R L Shapiro; D F Roses; J M Cohen; D Chhieng; M N Harris; J Waisman
Journal:  Cancer       Date:  2000-06-25       Impact factor: 6.860

Review 5.  The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Authors:  Friedegund Meier; Birgit Schittek; Silke Busch; Claus Garbe; Keiran Smalley; Kapaettu Satyamoorthy; Gang Li; Meenhard Herlyn
Journal:  Front Biosci       Date:  2005-09-01

6.  Invasive melanoma in Cdk4-targeted mice.

Authors:  R Sotillo; J F García; S Ortega; J Martin; P Dubus; M Barbacid; M Malumbres
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

Review 7.  Melanoma etiology: where are we?

Authors:  Margaret A Tucker; Alisa M Goldstein
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

8.  Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice.

Authors:  Elke Hacker; H Konrad Muller; Nicole Irwin; Brian Gabrielli; Douglas Lincoln; Sandra Pavey; Marianne Broome Powell; Marcos Malumbres; Mariano Barbacid; Nicholas Hayward; Graeme Walker
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

Review 9.  Molecular events in melanoma development and progression.

Authors:  F Meier; K Satyamoorthy; M Nesbit; M Y Hsu; B Schittek; C Garbe; M Herlyn
Journal:  Front Biosci       Date:  1998-09-15

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  10 in total

1.  Therapeutic strategies for targeting ras proteins.

Authors:  Stephan Gysin; Megan Salt; Amy Young; Frank McCormick
Journal:  Genes Cancer       Date:  2011-03

Review 2.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

3.  CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

Authors:  Stacey J Baker; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2012-11

Review 4.  Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.

Authors:  Xia-Qing Xu; Xiao-Hui Pan; Ting-Ting Wang; Jian Wang; Bo Yang; Qiao-Jun He; Ling Ding
Journal:  Acta Pharmacol Sin       Date:  2020-06-05       Impact factor: 6.150

5.  Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Authors:  Jackson R Taylor; Brian D Lehmann; William H Chappell; Stephen L Abrams; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2011-08

6.  Molecular damage in cancer: an argument for mTOR-driven aging.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2011-12       Impact factor: 5.682

Review 7.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

Review 8.  Melanoma: from melanocyte to genetic alterations and clinical options.

Authors:  Corine Bertolotto
Journal:  Scientifica (Cairo)       Date:  2013-12-12

Review 9.  Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.

Authors:  Andrea J McKinney; Sheri L Holmen
Journal:  Chin J Cancer       Date:  2011-03

Review 10.  CDK4: a master regulator of the cell cycle and its role in cancer.

Authors:  Stacey J Baker; Poulikos I Poulikakos; Hanna Y Irie; Samir Parekh; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2022-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.